News blog

New risk assessment for Boston biocontainment lab

A US National Institutes of Health advisory panel has released a new risk assessment for a controversial high-security biocontainment lab located near  Boston’s bustling downtown core. The Draft Supplementary Risk Assessment for the Boston University National Emerging Infectious Diseases Laboratories (NEIDL) was released on 24 February and is the next step in a long and process that may eventually lead to the National Biocontainment Laboratory being used for its intended purpose:  researching vaccines, therapeutics and diagnostics for emerging biological agents that could pose a serious public threat. 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.